Theravectys makes two appointments to strengthen executive committee

Hires a Head of Clinical Development and a Head of Strategy and Business Development

French biotechnology firm Theravectys, which specialises in the development of vaccines based on lentiviral vector technology, has appointed Paul Gineste as Head of Clinical Development and Pierre D'Epenoux as Head of Strategy and Business Development.

Gineste was formerly Director of Clinical Studies at AB Science and will head clinical development at Theravecyts to bring in-house vaccine candidates into the clinics.

D'Epenoux, formerly VP of Strategy and Business Development Europe at Sanofi, will be responsible for the firm's strategic planning as well as establishing alliances with leading research institutes and global strategic partners.

You may also like

Research & Development

Theravectys secures exclusive access to synthetic humanised nanobody library

Collaboration strengthens company’s proprietary immunotherapeutic platform
Regulatory

Theravectys is authorised to produce lentiviral vectors for clinical use and CAR-T cell therapies

French Agency for Medicines and Health Product Safety grants the company pharmaceutical manufacturing establishment status
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Subscribe now